LAVA Therapeutics NV (NASDAQ:LVTX) — Market Cap & Net Worth
Market Cap & Net Worth: LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (NASDAQ:LVTX) has a market capitalization of $45.77 Million ($45.77 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22221 globally and #4686 in its home market, demonstrating a -3.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LAVA Therapeutics NV's stock price $1.74 by its total outstanding shares 26305295 (26.31 Million). Analyse cash flow conversion of LAVA Therapeutics NV to see how efficiently the company converts income to cash.
LAVA Therapeutics NV Market Cap History: 2021 to 2025
LAVA Therapeutics NV's market capitalization history from 2021 to 2025. Data shows change from $144.68 Million to $45.77 Million (-36.23% CAGR).
Index Memberships
LAVA Therapeutics NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #640 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2130 of 3165 |
Weight: LAVA Therapeutics NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LAVA Therapeutics NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LAVA Therapeutics NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.09x
LAVA Therapeutics NV's market cap is 2.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $144.68 Million | $5.00 Million | -$45.35 Million | 28.94x | N/A |
| 2022 | $92.07 Million | $19.39 Million | -$31.91 Million | 4.75x | N/A |
| 2023 | $41.56 Million | $6.77 Million | -$41.87 Million | 6.14x | N/A |
| 2024 | $25.02 Million | $11.98 Million | -$25.11 Million | 2.09x | N/A |
Competitor Companies of LVTX by Market Capitalization
Companies near LAVA Therapeutics NV in the global market cap rankings as of May 4, 2026.
Key companies related to LAVA Therapeutics NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
LAVA Therapeutics NV Historical Marketcap From 2021 to 2025
Between 2021 and today, LAVA Therapeutics NV's market cap moved from $144.68 Million to $ 45.77 Million, with a yearly change of -36.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $45.77 Million | +82.97% |
| 2024 | $25.02 Million | -39.81% |
| 2023 | $41.56 Million | -54.86% |
| 2022 | $92.07 Million | -36.36% |
| 2021 | $144.68 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of LAVA Therapeutics NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.77 Million USD |
| MoneyControl | $45.77 Million USD |
| MarketWatch | $45.77 Million USD |
| marketcap.company | $45.77 Million USD |
| Reuters | $45.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more